Chitin-glucan improves important pathophysiological features of irritable bowel syndrome

doi:10.3748/wjg.v30.i16.2258

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 16

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (479)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-10) series, Tables (1-3) series.

Item

Count

PDF

HTML

369

Figures (1-10)

Tables (1-3)

Sum=418

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=39

Apr 28, 2024 (publication date) through May 7, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Apr 28, 2024; 30(16): 2258-2271
Published online Apr 28, 2024. doi: 10.3748/wjg.v30.i16.2258

Chitin-glucan improves important pathophysiological features of irritable bowel syndrome

Caroline Valibouze, Caroline Dubuquoy, Philippe Chavatte, Michaël Genin, Veronique Maquet, Salvatore Modica, Pierre Desreumaux, Christel Rousseaux

Caroline Valibouze, Department of Digestive Surgery and Transplantation, Lille University, Lille 59037, France

Caroline Dubuquoy, Christel Rousseaux, Intestinal Biotech Development, Faculté de Médicine, Lille 59045, France

Philippe Chavatte, U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, Lille 59000, France

Michaël Genin, ULR 2694-METRICS, Évaluation des Technologies de santé et des Pratiques Médicales, University of Lille, Lille 59000, France

Veronique Maquet, Salvatore Modica, KitoZyme SA, Institution Société Anonyme, Zone 2, Parc des Hauts Sarts, Rue de Milmort, Herstal 4040, Belgium

Pierre Desreumaux, Hepato-Gastroenterology Department, Lille University Hospital, Lille 59037, France

Author contributions: Valibouze C, Dubuquoy C, Rousseaux C, and Chavatte P acquired the data; Genin M supervised the statistical analyses; Valibouze C, Desreumaux P, and Rousseaux C drafted the manuscript; and all the authors interpreted the data and critically reviewed the manuscript; Intestinal Biotech Development supervised study coordination, data collection, and analysis; Chitin glucan was obtained from Kitozyme (SA).

Supported by the Service Public de Wallonie (SPW-EER, convention 8588, Belgium).

Institutional animal care and use committee statement: All the studies were approved by the Local Investigational Ethics Review Board (Approval Nord-Pas-de-Calais CEEA No. 75, Lille, France; protocol reference No. 352012 and No. 19-2009R); and French Government Agreement (Approval No. APAFIS#7542-20 17030609233680).

Conflict-of-interest statement: Desreumaux reports personal fees from Abbvie, personal fees from Abbott, personal fees from Amgen, personal fees from Biocodex, personal fees from Biofortis, personal fees from Biogen, personal fees from Biokuris, personal fees from Dr Falk, personal fees from Ferring, personal fees from Galapagos, personal fees from Fresenius, personal fees from Janssen, personal fees from Intestinal Biotech Development, personal fees from Kitozyme, personal fees from Lesaffre, personal fees from MSD, personal fees from Norgine, personal fees from Pfizer, personal fees from Sandoz, personal fees from Shire, personal fees from Takeda, personal fees from Tillotts, and personal fees from UCB outside the submitted work; Dr. Desreumaux has issued a patent (WO2009103884) issued; Christel Rousseaux is Chief Executive Officer at Intestinal Biotech Development; Veronique Maquet is a Product Development Manager at Kitozyme; Salvatore Modica is Chief Operating Officer at Biokuris, a spin-off company of Kitozyme; The other authors have nothing to disclose.

Data sharing statement: No additional data are available.

ARRIVE guidelines statement: The authors read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Christel Rousseaux, PhD, Researcher, Intestinal Biotech Development, Faculté de Médicine, Pole Recherche Amphi JK, Bd du Pr Jules Leclercq, Lille 59045, France. crousseaux@ibd-biotech.com

Received: January 25, 2024
Peer-review started: January 25, 2024
First decision: February 1, 2024
Revised: February 21, 2024
Accepted: March 28, 2024
Article in press: March 28, 2024
Published online: April 28, 2024

Core Tip

Core Tip: Currently available irritable bowel syndrome (IBS) treatments are often inadequate. Chitin-glucan is a novel, well-tolerated, non-digestible prebiotic considered a safe food ingredient by the European Food Safety Authority. This study suggests new capacities of chitin-glucan to target most pathophysiological mechanisms of IBS and its therapeutic potential as a promising new generation of prebiotics for patients with IBS or IBS-like symptoms.